Literature DB >> 11754398

Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression.

D Lavelle1, Y H Chen, M Hankewych, J DeSimone.   

Abstract

Histone deacetylase (HDAC) inhibitors cause growth arrest and apoptosis of cancer cells by both p21-dependent and independent mechanisms. Decreased expression of growth factor receptors may be a key factor in the p21-independent mechanism, although this has not been directly tested. We have tested the effects of sodium butyrate and trichostatin A on human myeloma cell lines and have observed G1 arrest and apoptosis associated with increased expression of p21(WAF1), Bax, Rb dephosphorylation, and decreased IL-6 receptor (IL-6R) expression. Experiments to determine the role of disruption of IL-6 signaling as a result of decreased IL-6 receptor expression in mediating these effects were conducted using a stable transfectant of the OPM-2 line which constitutively expressed the IL-6 receptor. Our results indicated that decreased IL-6R expression was not required for induction of p21(WAF1) or apoptosis. Thus, HDAC inhibitors appear to activate multiple cellular pathways, leading to growth arrest and apoptosis, and their use in the treatment of myeloma, particularly in combination with other agents, warrants further investigation. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11754398     DOI: 10.1002/ajh.1174

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  30 in total

1.  Gene modulation associated with inhibition of liver regeneration in hepatitis B virus X transgenic mice.

Authors:  Malgorzata Sidorkiewicz; Jean-Philippe Jais; Guilherme Tralhao; Serban Morosan; Carlo Giannini; Nicolas Brezillon; Patrick Soussan; Oona Delpuech; Dina Kremsdorf
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

2.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

3.  Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cells.

Authors:  Fei Zhao; Yan Chen; Ling-lan Zeng; Rui Li; Rong Zeng; Lu Wen; Yuan Liu; Chun Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-06       Impact factor: 6.150

4.  High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

Authors:  Yiming Zhou; Lijuan Chen; Bart Barlogie; Owen Stephens; Xiaosong Wu; David R Williams; Marie-Astrid Cartron; Frits van Rhee; Bijay Nair; Sarah Waheed; Mauricio Pineda-Roman; Yazan Alsayed; Elias Anaissie; John D Shaughnessy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

5.  Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.

Authors:  M Gupta; J J Han; M Stenson; L Wellik; T E Witzig
Journal:  Leukemia       Date:  2011-11-25       Impact factor: 11.528

6.  The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.

Authors:  Matthias Ocker; Abdullah Alajati; Marion Ganslmayer; Steffen Zopf; Mike Lüders; Daniel Neureiter; Eckhart G Hahn; Detlef Schuppan; Christoph Herold
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-08       Impact factor: 4.553

Review 7.  The emerging role of lysine acetylation of non-nuclear proteins.

Authors:  Pierre Close; Catherine Creppe; Magali Gillard; Aurélie Ladang; Jean-Paul Chapelle; Laurent Nguyen; Alain Chariot
Journal:  Cell Mol Life Sci       Date:  2010-01-16       Impact factor: 9.261

8.  Role of the translational repressor 4E-BP1 in the regulation of p21(Waf1/Cip1) expression by retinoids.

Authors:  Padma Kannan-Thulasiraman; Blazej Dolniak; Surinder Kaur; Antonella Sassano; Dhananjaya V Kalvakolanu; Nissim Hay; Leonidas C Platanias
Journal:  Biochem Biophys Res Commun       Date:  2008-02-15       Impact factor: 3.575

9.  Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.

Authors:  Shaoteng Han; Takuya Fukazawa; Tomoki Yamatsuji; Junji Matsuoka; Hiroyuki Miyachi; Yutaka Maeda; Mary Durbin; Yoshio Naomoto
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

10.  Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma.

Authors:  Ken-Ichi Kitazoe; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Takeshi Harada; Ayako Nakano; Kyoko Takeuchi; Toshihiro Hashimoto; Shuji Ozaki; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.